Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04667247 · ClinicalTrials.gov registry record · Phase 1
RCT of Fomitopsis Officinalis and Trametes Versicolor to Treat COVID-19
A Phase 1 study of COVID-19, sponsored by Gordon Saxe.
- Completed
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 2
- Study locations
NCT04667247 is a Phase 1 study of COVID-19 that has completed, run by Gordon Saxe. The registered enrollment target is 54 participants, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT04667247, a Phase 1 study of COVID-19, has completed, sponsored by Gordon Saxe.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to evaluate two polypore mushrooms, Fomitopsis officinalis and Trametes versicolor (FoTv), to treat COVID-19-positive outpatients with mild-to-moderate symptoms assigned to self-quarantined and home management. The study aims to establish the safety and feasibility of the use of FoTv vs placebo in 66 total subjects.
Conditions Studied
Interventions
- DRUG FoTv
Study Locations (2)
California
- University of California, Los Angeles - Los Angeles
- University of California, San Diego - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2020-12-23 |
| Est. Completion | 2022-05-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04667247
The ClinicalTrials.gov registry entry for NCT04667247 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 55,214-participant average among 203 other COVID-19 trials with a reported enrollment target (100% lower). The listed sponsor is Gordon Saxe, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which FoTv is the first listed.
NCT04667247 reports 2 study locations spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04667247 about?
NCT04667247 is a clinical study titled "RCT of Fomitopsis Officinalis and Trametes Versicolor to Treat COVID-19". This is a multi-center, randomized, double-blind, placebo-controlled clinical trial to evaluate two polypore mushrooms, Fomitopsis officinalis and Trametes versicolor (FoTv), to treat COVID-19-positive outpatients with mild-to-moderate symptoms assigned to self-quarantined and home management. The s...
What is the current status of trial NCT04667247?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2020-12-23. Estimated completion is 2022-05-04.
What conditions does trial NCT04667247 study?
This clinical trial studies the following conditions: COVID-19.
What interventions are being tested in trial NCT04667247?
The interventions under investigation include: FoTv (DRUG).
Who is sponsoring clinical trial NCT04667247?
This trial is sponsored by Gordon Saxe, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04667247 being conducted?
This trial has 2 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Positron Emission Tomography (PET) Imaging of Thrombosis
RECRUITING · Phase 1
-
A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes
RECRUITING · Phase 1
-
A Phase 1/2A, Randomized Study of a T Follicular Helper (TFH)-Targeting Genetic Vaccine Strategy Designed to Induce Broad, Durable Immune Responses
RECRUITING · Phase 1
-
A Study Evaluating MDX2301 in Healthy Adults and Adults at Higher Risk for Severe COVID-19.
RECRUITING · Phase 1
-
A First in Human Study to Evaluate the Safety and Immunogenicity of RBM-001 in Healthy Adult Volunteers
ACTIVE NOT RECRUITING · Phase 1
-
Supplemental Citicoline Administration to Reduce Lung Injury Efficacy Trial (SCARLET)
ACTIVE NOT RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.